xCures, Inc.

xCures, Inc. is an innovative healthcare technology company specializing in AI-driven solutions that extract and standardize clinical data from diverse medical records to enhance patient-specific insights and support healthcare professionals' decision-making. Founded in 2018 in San Francisco, US, xCures focuses on transforming unstructured health data into actionable datasets for the healthcare sector. The company was co-founded by Jeff Shrager and Marty Tenenbaum and is currently led by CEO Mika Newton.

xCures has successfully raised a total of USD 12. 69 mn in funding across multiple rounds, with the latest being a Series A round on June 23, 2021, led by Boehringer Ingelheim Venture, alongside participation from Harmonix, Metaplanet Holdings, and Vanedge Capital. The firm has completed a total of 5 deals to date, and its current valuation stands at USD 24. 165 mn.

xCures specializes in advanced AI-driven healthcare solutions, primarily focusing on the extraction, standardization, and structuring of clinical data from diverse medical records. Their core product integrates sophisticated information extraction models that transform unstructured health information into clear, actionable datasets. These datasets provide healthcare professionals with patient-specific insights, enhancing clinical clarity and decision-making capabilities. The platform is designed to cater to a variety of stakeholders within the healthcare ecosystem, including hospitals, clinics, and research institutions, primarily serving markets in North America and Europe.

By prioritizing performance metrics and implementing rigorous quality control measures, xCures ensures that the data extraction process not only meets but exceeds industry standards, fostering trust among end users who rely on accurate clinical information for patient care. The revenue model for xCures is built on B2B transactions, primarily through subscription-based partnerships with healthcare providers and organizations. Clients engage with xCures to integrate their AI healthcare software into existing workflows, paying for ongoing access to the platform and its capabilities. The pricing structure accommodates a range of organizational sizes and needs, allowing clients to select plans tailored to their specific requirements.

These transactions typically involve initial setup fees along with recurring payments linked to the volume of data processed or the number of users accessing the system. By delivering a robust solution that aids in precision oncology and other healthcare sectors, xCures positions itself as a vital resource for organizations looking to leverage health data effectively. xCures plans to utilize the USD 12. 69 mn raised in its Series A funding to accelerate the adoption and further development of its AI-Powered platform for precision oncology decision-making.

The company aims to expand its product offerings with new enhancements and features that are currently being designed. Geographically, xCures is targeting expansions into additional markets across Europe and North America, with a strategic timeline for growth set for the next two years. These efforts are aligned with their goal of providing improved healthcare solutions and further establishing their presence in the healthcare technology space.